2
Feb
2023

GSK, Lilly Win FDA Approvals, Magenta For Sale, and a Colossal Series B

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Pfizer Acquires Seagen, Sanofi & Novo Cut Insulin Prices, & Illumina’s Proxy Fight
SVB’s Dark Day, Biogen’s Leadership Change, and a Plan to Crush HepC
Lilly Cuts Insulin Prices, Reata’s Dramatic FDA Approval, & Seagen M&A Rumors
VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions